Marksans Pharma UK subsidiary gets marketing authorization for oral solution

Marksans Pharma Limited announced on November 20, 2025, that its wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution. This authorization marks a significant regulatory milestone for the company's expansion in the UK market.

Marksans Pharma, headquartered in Mumbai, India, specializes in the research, manufacturing, and marketing of generic pharmaceutical formulations globally. The company's manufacturing facilities in India, USA, and UK are approved by major regulatory bodies, including the USFDA, UKMHRA, and Australian TGA.

The company's product portfolio spans various therapeutic segments, including CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological, Anti-allergies, Upper respiratory, Oncology, and Anti-biotic. Marksans Pharma markets these products internationally, strengthening its global pharmaceutical presence.